Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • avastin

    Tag: Avastin

    You Searched For "avastin"
    USFDA Accepts Biocon, Mylans application for review of   Proposed Biosimilar of Bevacizumab

    USFDA Accepts Biocon, Mylan's application for review of Proposed Biosimilar of Bevacizumab

    Medical Dialogues Bureau10 March 2020 1:15 PM IST
    Biocon Ltd. and Mylan N.V. announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License Application (BLA)...
    Tecentriq-Avastin cocktail helps liver cancer patients live longer: Roche

    Tecentriq-Avastin cocktail helps liver cancer patients live longer: Roche

    Medical Dialogues Bureau25 Nov 2019 9:00 AM IST
    Median overall survival for patients with unresectable hepatocellular carcinoma (HCC), or that which cannot be surgically removed, getting Tecentriq...
    Roche Tecentriq, Avastin combo to increase overall survival, progression-free survival in HCC

    Roche Tecentriq, Avastin combo to increase overall survival, progression-free survival in HCC

    Medical Dialogues Bureau22 Oct 2019 9:50 AM IST
    Roche, in its recent release, in 2018, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Tecentriq in...
    Roche touts drugs pipeline, rules out Merger and Acquisition just to boost sales

    Roche touts drugs pipeline, rules out Merger and Acquisition just to boost sales

    Medical Dialogues Bureau7 Sept 2019 9:15 AM IST
    Roche has twice upgraded 2019 sales forecasts, the latest time to mid- to high-single-digit percentage rate growth, as medicines including Ocrevus for...
    Roche lymphoma drug drives high remission rate, longer survival: study

    Roche lymphoma drug drives high remission rate, longer survival: study

    Ruby Khatun Khatun12 Dec 2017 10:00 AM IST
    An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced,...
    Roche drug cocktail doubles chance of holding lung cancer at bay

    Roche drug cocktail doubles chance of holding lung cancer at bay

    Ruby Khatun Khatun9 Dec 2017 9:45 AM IST
    ZURICH: Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease...
    Roche stock up 12 billion dollars on cancer, hemophilia trials; rivals hit

    Roche stock up 12 billion dollars on cancer, hemophilia trials; rivals hit

    Ruby Khatun Khatun22 Nov 2017 10:00 AM IST
    ZURICH: Roche shares were lifted on Monday by two trial wins for its new cancer and hemophilia drugs, potential blockbusters that the Swiss drugmaker...
    Novartis posts eye drug data amid play for Eylea

    Novartis posts eye drug data amid play for Eylea's turf

    Ruby Khatun Khatun14 Nov 2017 9:45 AM IST
    ZURICH: Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new...
    Roche MS drug Ocrevus wins European panel backing

    Roche MS drug Ocrevus wins European panel backing

    Ruby Khatun Khatun13 Nov 2017 10:02 AM IST
    ZURICH: Swiss drugmaker Roche on Friday won a key European panel's recommendation for its multiple sclerosis drug Ocrevus, which is on track for...
    Roche eye drug fails late-stage trial in blow to pipeline

    Roche eye drug fails late-stage trial in blow to pipeline

    Ruby Khatun Khatun11 Sept 2017 9:32 AM IST
    ZURICH: A drug Roche had hoped would prevent loss of vision and become a big seller failed a late-stage trial, leading some analysts to say on Friday...

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok